TY - JOUR
T1 - Pathology of Drug-Eluting Stents in Humans. Delayed Healing and Late Thrombotic Risk
AU - Joner, Michael
AU - Finn, Aloke V.
AU - Farb, Andrew
AU - Mont, Erik K.
AU - Kolodgie, Frank D.
AU - Ladich, Elena
AU - Kutys, Robert
AU - Skorija, Kristi
AU - Gold, Herman K.
AU - Virmani, Renu
N1 - Funding Information:
Supported by Medtronic AVE; Guidant; Abbott; W. L. Gore; General Electric; diaDexus; Takeda; Atrium Medical Corporation; Invatec; ev3; TopSpin Medical (Israel) Ltd.; Boston Scientific; NDC Cordis Corporation; Novartis; Paracor Medical, Inc.; C. R. Bard, Inc.; and Orbus Medical Technologies. Dr. Virmani is a consultant for Medtronic AVE; Guidant; Abbott Laboratories; W. L. Gore; Terumo; TopSpin Medical (Israel) Ltd.; Inflow Diagnostic; Prescient Medical; CryoVascular Systems, Inc.; and Volcano Therapeutics Inc.
PY - 2006/7/4
Y1 - 2006/7/4
N2 - Objectives: This study examined human drug-eluting stents (DES) to determine the long-term effects of these stents on coronary arterial healing and identified mechanisms underlying late stent thrombosis (LST). Background: Although DES reduce the need for repeat revascularization compared with bare-metal stents (BMS), data suggest the window of thrombotic risk for Cypher (Cordis Corp., Miami Lakes, Florida) and Taxus (Boston Scientific Corp., Natick, Massachusetts) DES extends far beyond that for BMS. Methods: From a registry of 40 autopsies of DES (68 stents), 23 DES cases of >30 days duration were compared with 25 matched autopsies of BMS implantation. Late stent thrombosis was defined as an acute thrombus within a stent >30 days old. Results: Of 23 patients with DES >30 days old, 14 had evidence of LST. Cypher and Taxus DES showed greater delayed healing characterized by persistent fibrin deposition (fibrin score 2.3 ± 1.1 vs. 0.9 ± 0.8, p = 0.0001) and poorer endothelialization (55.8 ± 26.5%) compared with BMS (89.8 ± 20.9, p = 0.0001). Moreover, DES with LST showed more delayed healing compared with patent DES. In 5 of 14 patients suffering LST, antiplatelet therapy had been withdrawn. Additional procedural and pathologic risk factors for LST were: 1) local hypersensitivity reaction; 2) ostial and/or bifurcation stenting; 3) malapposition/incomplete apposition; 4) restenosis; and 5) strut penetration into a necrotic core. Conclusions: The Cypher and Taxus DES result in delayed arterial healing when compared with BMS of similar implant duration. The cause of DES LST is multifactorial with delayed healing in combination with other clinical and procedural risk factors playing a role.
AB - Objectives: This study examined human drug-eluting stents (DES) to determine the long-term effects of these stents on coronary arterial healing and identified mechanisms underlying late stent thrombosis (LST). Background: Although DES reduce the need for repeat revascularization compared with bare-metal stents (BMS), data suggest the window of thrombotic risk for Cypher (Cordis Corp., Miami Lakes, Florida) and Taxus (Boston Scientific Corp., Natick, Massachusetts) DES extends far beyond that for BMS. Methods: From a registry of 40 autopsies of DES (68 stents), 23 DES cases of >30 days duration were compared with 25 matched autopsies of BMS implantation. Late stent thrombosis was defined as an acute thrombus within a stent >30 days old. Results: Of 23 patients with DES >30 days old, 14 had evidence of LST. Cypher and Taxus DES showed greater delayed healing characterized by persistent fibrin deposition (fibrin score 2.3 ± 1.1 vs. 0.9 ± 0.8, p = 0.0001) and poorer endothelialization (55.8 ± 26.5%) compared with BMS (89.8 ± 20.9, p = 0.0001). Moreover, DES with LST showed more delayed healing compared with patent DES. In 5 of 14 patients suffering LST, antiplatelet therapy had been withdrawn. Additional procedural and pathologic risk factors for LST were: 1) local hypersensitivity reaction; 2) ostial and/or bifurcation stenting; 3) malapposition/incomplete apposition; 4) restenosis; and 5) strut penetration into a necrotic core. Conclusions: The Cypher and Taxus DES result in delayed arterial healing when compared with BMS of similar implant duration. The cause of DES LST is multifactorial with delayed healing in combination with other clinical and procedural risk factors playing a role.
UR - http://www.scopus.com/inward/record.url?scp=33745233024&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2006.03.042
DO - 10.1016/j.jacc.2006.03.042
M3 - Article
C2 - 16814667
AN - SCOPUS:33745233024
SN - 0735-1097
VL - 48
SP - 193
EP - 202
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 1
ER -